SEEL [NASD]
Seelos Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.60 Insider Own3.20% Shs Outstand105.53M Perf Week-1.00%
Market Cap74.36M Forward P/E- EPS next Y-0.56 Insider Trans2.33% Shs Float100.97M Perf Month8.52%
Income-60.90M PEG- EPS next Q-0.18 Inst Own40.60% Short Float9.51% Perf Quarter-21.88%
Sales- P/S- EPS this Y-70.30% Inst Trans0.17% Short Ratio7.38 Perf Half Y-59.85%
Book/sh0.43 P/B1.52 EPS next Y13.60% ROA-74.90% Target Price6.17 Perf Year-77.04%
Cash/sh0.54 P/C1.20 EPS next 5Y- ROE-94.30% 52W Range0.48 - 3.10 Perf YTD-59.85%
Dividend- P/FCF- EPS past 5Y54.00% ROI- 52W High-78.89% Beta2.42
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low36.27% ATR0.06
Employees16 Current Ratio7.00 Sales Q/Q- Oper. Margin- RSI (14)47.93 Volatility9.37% 9.54%
OptionableYes Debt/Eq0.42 EPS Q/Q52.10% Profit Margin- Rel Volume1.02 Prev Close0.68
ShortableYes LT Debt/Eq0.33 Earnings- Payout- Avg Volume1.30M Price0.65
Recom1.70 SMA20-4.71% SMA502.15% SMA200-50.73% Volume1,322,787 Change-3.79%
Sep-27-21Upgrade ROTH Capital Neutral → Buy $2.50 → $8
Jul-01-21Initiated Guggenheim Buy $8
Jun-01-21Initiated Cantor Fitzgerald Overweight $10
May-17-21Downgrade ROTH Capital Buy → Neutral
Mar-30-21Initiated B. Riley Securities Buy $15
Nov-14-19Initiated The Benchmark Company Speculative Buy $4
May-14-19Initiated ROTH Capital Buy
Jun-09-22 08:00AM  
Jun-06-22 12:47PM  
May-18-22 08:00AM  
May-12-22 08:00AM  
Apr-22-22 11:00AM  
Apr-11-22 08:00AM  
Mar-08-22 08:00AM  
Mar-07-22 08:00AM  
Feb-28-22 08:00AM  
Dec-21-21 04:05PM  
Dec-16-21 08:00AM  
Dec-06-21 08:01AM  
Nov-29-21 09:00AM  
Nov-24-21 11:18AM  
08:16AM  
07:16AM  
Nov-23-21 07:03AM  
Nov-10-21 08:00AM  
Nov-09-21 11:18AM  
Nov-08-21 09:19AM  
08:00AM  
Nov-02-21 08:00AM  
Oct-25-21 02:00PM  
Oct-01-21 08:00AM  
Sep-27-21 12:59PM  
Sep-22-21 10:02AM  
Sep-21-21 03:25PM  
Sep-09-21 08:00AM  
Sep-02-21 08:00AM  
Sep-01-21 08:00AM  
Aug-09-21 10:47AM  
08:00AM  
Jul-14-21 12:57PM  
08:00AM  
Jul-07-21 11:12AM  
07:00AM  
Jul-06-21 04:47PM  
08:00AM  
Jun-29-21 02:42PM  
Jun-28-21 07:00AM  
Jun-01-21 01:22PM  
08:00AM  
May-27-21 07:00AM  
May-24-21 04:05PM  
08:33AM  
May-21-21 08:00AM  
May-20-21 08:19AM  
May-19-21 04:01PM  
08:54AM  
May-17-21 06:52PM  
09:17AM  
06:00AM  
May-10-21 08:00AM  
Apr-20-21 07:00AM  
Apr-19-21 08:00AM  
Apr-15-21 09:00AM  
Apr-09-21 08:34AM  
Apr-06-21 07:00AM  
Mar-12-21 12:32PM  
11:44AM  
Mar-05-21 09:00AM  
Feb-18-21 08:38AM  
08:14AM  
07:00AM  
Feb-17-21 08:00AM  
Feb-01-21 08:00AM  
Jan-29-21 08:00AM  
Jan-28-21 10:07AM  
Jan-27-21 08:59AM  
08:00AM  
Jan-26-21 08:30AM  
Jan-25-21 04:01PM  
Jan-22-21 09:00AM  
Jan-15-21 08:30AM  
Jan-06-21 08:45AM  
Jan-05-21 09:00AM  
Dec-21-20 09:00AM  
Dec-15-20 09:00AM  
Dec-14-20 09:00AM  
Dec-11-20 10:00AM  
Dec-08-20 09:00AM  
Dec-02-20 09:00AM  
Nov-29-20 11:41AM  
Nov-19-20 08:45AM  
Nov-09-20 09:24AM  
Oct-26-20 09:00AM  
Oct-22-20 09:00AM  
Sep-28-20 03:30PM  
Sep-23-20 09:00AM  
Sep-14-20 09:00AM  
Sep-10-20 09:00AM  
Sep-09-20 02:00PM  
Sep-04-20 09:08AM  
Aug-28-20 08:00AM  
Aug-25-20 11:00AM  
Aug-10-20 09:15AM  
Jul-21-20 09:00AM  
Jul-16-20 04:31PM  
04:30PM  
Jun-25-20 08:00AM  
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Connor Daniel J.DirectorJun 01Buy0.6116,0009,78916,000Jun 02 04:29 PM
Mehra RajSee RemarksMar 31Buy0.8566,66756,8403,281,546Mar 31 04:34 PM